Wyeth Ends Bifeprunox For Schizophrenia Development Deal With Solvay
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth decides drug candidate has inadequate commercial value for both companies to share, firm tells "The Pink Sheet" DAILY.
You may also be interested in...
Solvay Analyzing “Various Options” For Its Pharma Unit
Belgian firm, which co-markets TriLipix and TriCor with Abbott, confirms it is in discussions with third-parties.
Solvay Analyzing “Various Options” For Its Pharma Unit
Belgian firm, which co-markets TriLipix and TriCor with Abbott, confirms it is in discussions with third-parties.
Curis To Continue Focus On Oncology After Wyeth Ends Hedgehog Venture
Cambridge, Mass.-based Curis seeks a new partner to continue small molecule and protein hedgehog agonist development in cardiovascular/nervous system disorders.